Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628945 | 1.00 | LPL (0.38) | LPLLIPGALPLSNCAIRAK4 | |
| SCHEMBL4561669 | 0.80 | SNCA (0.47) | LPLLIPGALPLSNCAIRAK4 | |
| SCHEMBL14842080 | 0.78 | CYP1A2 (0.45) | LPLLIPGALPLSNCAIRAK4 | |
| SCHEMBL6033638 | 0.77 | LPL (0.47) | LPLLIPGALPLSNCAIRAK4 | |
| SCHEMBL14721612 | 0.77 | EGFR (0.43) | LPLLIPGALPLSNCAIRAK4 | |
| SCHEMBL7601195 | 0.76 | LIPG (0.58) | LPLLIPGSNCAIRAK4ESR2 | |
| SCHEMBL20622696 | 0.75 | LPL (0.40) | LPLLIPGALPLSNCAIRAK4 | |
| SCHEMBL30315449 | 0.75 | LPL (0.40) | LPLLIPGALPLSNCAIRAK4 | |
| SCHEMBL14447442 | 0.74 | LPL (0.50) | LPLLIPGSNCAESR2CA1 | |
| SCHEMBL26750740 | 0.73 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519384-B1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORP (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20240191211-A1 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2023215497-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215514-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | PROMEGA CORPORATION | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357266-A1 | PHOTOACTIVATABLE COMPOUNDS AND USES THEREOF | BTD, HLCS, TYR | LPL 2537/4885LIPG 1515/4885ALPL 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.